Reframing the Significance of Airway Hyperresponsiveness in Severe Asthma

Grant ID: 71024551
Final Online Enduring Outcomes Summary
Table of Contents
Final Outcomes Summary – Online Enduring Outcomes

• Executive Summary (Slide 3)
• Program Features (Slide 4)
• Audience Generation (Slide 5)
• Online Enduring Q1 Outcomes (Slide 6)
  • Educational Impact Summary (Slides 7-8)
  • Program Insights (Slide 9)
  • Level 1 – Participation (Slides 10-11)
  • Level 2 – Satisfaction (Slide 12)
  • Level 3&4 – Knowledge and Competence (Slides 13-21)
  • Level 4 – Competence (Slides 22-23)
  • Evaluation Survey Results (Slides 24-25)
• Accreditation (Slide 26)
Executive Summary
Final Outcomes Summary – Online Enduring Outcomes

Program Overview
This program was designed to engage specialty health care practitioners in pulmonology and allergy in the topic of airway hyperresponsiveness (AHR), with three activities endured on Peer Audience, which excels at reaching specialists:
- Two 15-minute video-based activities to help learners understand airway hyperresponsiveness, its clinical significance, and emerging treatments; these incorporate micro-learning to deliver a high-impact, accessible message that is sensitive to health care providers’ time constraints.
- One certified text-based monograph activity encompassing the content of the two video-based activities that will convey the nuances of airway hyperresponsiveness and appropriate therapies. This activity appeals to health care providers’ strong preference for text-based learning.
The video-based activities also incorporate presentation of case scenarios and 2D/3D animation clips to illustrate and demystify the complexity of our new understanding of severe asthma pathophysiology, the inflammatory cascade, and hyperresponsiveness.

Online Enduring Dates:
May 27, 2022 – May 27, 2023 (Peer Audience)

Program Faculty
Michael E. Wechsler, MD, MMSc
Director of The Cohen Family Asthma Institute and Professor of Medicine
Division of Pulmonary, Critical Care, & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, Colorado

Flavia Cecilia Lega Hoyte, MD
Associate Professor
Fellowship Training Program Director
Division of Allergy & Clinical Immunology
Department of Medicine
National Jewish Health
Denver, Colorado

Learning Objectives
- Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma
- Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management
- Discuss the implications of AHR for treatment selection in severe asthma
- Compare the effects of current and emerging biologic therapies on AHR in clinical studies

Target Audience & Accreditation
Target Audience: Pulmonologists, Allergists, and Nurse Practitioners and Physician Assistants in those specialties who treat severe asthma.

National Jewish Health designates each video-based activity for a maximum of 0.25 AMA PRA Category 1 Credit™ and the monograph activity for 0.5 AMA PRA Category 1 Credit™
Program Features
Final Outcomes Summary – Online Enduring Outcomes

**Animation Clips**

**Patient Case Scenarios**

**Case 2**

- 42-year-old woman
- Severe refractory eosinophilic asthma despite ICS/LABA
- Anti IL-5 therapy with history of eosinophilia to 450
- Despite Eos now reduced to 0, she continues to have coughing and wheezing, particularly in response to exposure to smoke and perfumes, or on high ozone days

**Monograph**

**Introduction**

Asthma affects over 23 million people in the United States and is characterized by wheezing, coughing, and chest tightness. Asthma symptoms are brought forth by airway inflammation, bronchoconstriction, and airway hyperresponsiveness (AHR), which is sometimes described as airway "windchill." AHR is underdiagnosed by most clinicians. However, AHR affects patients with asthma daily and is an important asthma feature to consider when optimizing management.

Asthma involves narrowing of the airways. Asthma narrowing is caused primarily by the constriction of smooth muscle that surrounds the airway. Airway narrowing results in the symptoms of cough, shortness of breath, chest tightness, and wheezing. Asthma worsens in response to avoid airway attack, airway narrowing in particular is pronounced and severe.

**Definition and clinical significance of AHR**

AHR reflects the predisposition of individuals with asthma to narrow unexpectedly in response to stimuli that would produce little or no effect in healthy subjects. AHR is a heightened bronchomotor/intrinsic response to either direct or indirect stimuli that can be demonstrated in patients with either episodic or active/asthmatic asthma.1,2 Understanding the factors that contribute to AHR provides an opportunity to improve asthma control and reduce disease progression.

AHR is a cardinal feature of asthma that is associated with reduced lung function.1 It is also associated with increased wheezing and asthma severity.2 A higher risk for asthma development,2 and suboptimal responsiveness to asthma therapy, including inhaled corticosteroids (ICS).3,4 in patients with severe asthma. AHR is associated with the occurrence of asthma exacerbations and can be exacerbated during exacerbations.

Measurement of AHR with bronchoprovocation testing (BPT) can be used to establish a diagnosis of asthma, characterize the type of asthma, and evaluate asthma severity. Assessing AHR provides an opportunity to improve asthma control and lung function and to reduce disease progression by identifying treatments that ameliorate AHR symptoms, particularly in patients who respond poorly to treatment with ICS.

**Role of the epithelial alternans in AHR**

In susceptible individuals, AHR may increase after inhalational exposure to different types of stimuli that include respiratory pathogens (eg, viruses, bacteria), allergens (eg, dust mites, cockroaches, animal dander, molds, pollens), and air pollutants (eg, tobacco, dust, chemicals, particularly TS–1)

**Increased angiogenesis as well as an alteration in the synthetic and contractile function of muscle cells**

IL-25, IL-33, TSLP, ALARMS

**Type 2 Cytokines**

IL-4, IL-5, IL-13

**Type 2 Innate Lymphoid Cells (ILC2)**

PGD2, IL-33R(ST2), IL-25, IL-33

**Release of cytokines**

TSLP, IL-25, and IL-33

**Histamines**

Type 2 Cell

Th2 Cell

B Cell
**Audience Generation**

Final Outcomes Summary – Online Enduring Outcomes

**Personalized targeting tools** across numerous tactics reach HCPs by leveraging demographic data (such as location, profession, specialty) and behavioral data (such as learner participation history, areas of interest).

- PeerAudience recruitment: emails, network marketing, social media, search engine advertising, dedicated landing page
- Promotional video clip on social media platforms
- Featured in Pulmonary Highlights publication
- Social media ads and posts
- Dedicated landing page on NJH website
- Online Course Spotlight
- Course spotlight in emails to NJH database
- National Jewish Health @NJHealth - Jul 1

Pulmonologists and #Saltsight, we're taking you back to that Airway Hyperresponsiveness you told in med school with our new online course – Reframing the Significance of Airway Hyperresponsiveness in Severe Asthma. View this #ProCME activity led by National Jewish Health allergist and immunologist Flavia Hoyle, MD and pulmonologist Michael Wechsler, MD, MHSc.

https://njh.org/CME

#pulmonaryhighlights

NOW IS THE TIME TO BOOST UP YOUR KNOWLEDGE
Online Enduring Program
Final Outcomes Summary – Online Enduring Outcomes

PeerAudience
5/27/2022 – 5/27/2023
https://www.pro-c.me/180200652?Promocode=800

Pro·CME

EDUCATIONAL SERIES
Reframing the Significance of Airway Hyperresponsiveness in Severe Asthma

ACTIVITY 1 - 0.25 Credit(s)
Airway Hyperresponsiveness
Michael E. Wechsler, MD, MMSc
Flavia Cecilia Lega Hoyte, MD

ACTIVITY 2 - 0.25 Credit(s)
Clinical Significance of Airway Hyperresponsiveness
Michael E. Wechsler, MD, MMSc
Flavia Cecilia Lega Hoyte, MD

ACTIVITY 3 - 0.5 Credit(s)
Monograph
Michael E. Wechsler, MD, MMSc
Flavia Cecilia Lega Hoyte, MD
Educational Impact Summary (Across 3 Activities)

Final Outcomes Summary – Online Enduring Outcomes

**Participation**
- MD/DO=2,097
- Other=28
- Total Learners=2,125
- 99% of learners were physicians

**Learner Guarantee**
- 1,400
  - 400 allergy
  - 1,000 pulmonology

**Learner Actuals**
- 2,125
  - 888 allergy
  - 1,209 pulmonology

**Evaluation**
- N=228
  - Met their educational needs (98%)
  - Reinforced or improved current skills (98%)
  - Improved ability to treat patients (96%)

**Confidence Gain by Objective**
- Define AHR and its relationship to epithelial cell function...
  - Before activity (AVG N=148) 60% 95%
  - After activity (AVG N=72) 60% 95%
- Evaluate the role of bronchoprovocation challenge testing
  - Before activity (AVG N=148) 59% 94%
  - After activity (AVG N=72) 59% 94%
- Discuss the implications of AHR for treatment selection
  - Before activity (AVG N=148) 59% 93%
  - After activity (AVG N=72) 59% 93%
- Compare effects of current and emerging biologic therapies on AHR
  - Before activity (AVG N=148) 52% 91%
  - After activity (AVG N=72) 52% 91%

**Potential Impact To**
- 99,892 Patient Visits This Year

**Evaluation respondents intend to make changes to practice as a result of the activity**
- 92% N=226
## Educational Impact Summary (Across 3 Activities)

**Final Outcomes Summary – Online Enduring Outcomes**

<table>
<thead>
<tr>
<th>Patient Impact</th>
<th>Educational Impact</th>
<th>Practice Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>224</strong> evaluation respondents</td>
<td><strong>71%</strong> relative knowledge gain seen from learners in defining AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma (AVG N=78)</td>
<td><strong>92%</strong> intend to make changes in practice as a result of what they learned (N=226)</td>
</tr>
<tr>
<td>Who see <strong>1,921</strong> severe asthma patients weekly</td>
<td><strong>51%</strong> relative knowledge gain in evaluating the role of bronchoprovocation challenge testing in asthma diagnosis and management (AVG N=78)</td>
<td><strong>97%</strong> indicated the activity gave tools and strategies to apply in practice (N=228)</td>
</tr>
<tr>
<td>Which translates to <strong>99,892</strong> potential patient visits annually</td>
<td><strong>54%</strong> relative knowledge gain seen from learners in discussing the implications of AHR for treatment selection in severe asthma (AVG N=78)</td>
<td><strong>60%</strong> relative gain in confidence across learning objectives (AVG N=72)</td>
</tr>
<tr>
<td></td>
<td><strong>89%</strong> relative knowledge gain in comparing effects of current and emerging biologic therapies on AHR in clinical studies (AVG N=78)</td>
<td></td>
</tr>
</tbody>
</table>
• Learner reach for this activity was 52% higher than expected, and 99% of learners were in the target audience, indicating significant interest in the topic of airway hyperresponsiveness among pulmonologists and allergists.

• Knowledge gains were highest among allergists, at 82% overall relative knowledge gain vs. 48% overall relative knowledge gain among pulmonologists (across all learning objectives and all 3 activities).
  
  o Pulmonologists, however, had higher baseline knowledge across all learning objectives as demonstrated by pre-test scores.

• A gap may still exist with regard to the effects of current and emerging biologic therapies on AHR, as an average of 32% of learners were unable to answer correctly at post-test.
Level (1) Outcomes: Participation (Degree)
Final Outcomes Summary – Online Enduring Outcomes

99% of learners were physicians
Learners = individuals who entered the digital interface

Total Learners (across the 3 activities): 2,125

<table>
<thead>
<tr>
<th></th>
<th>MD/DO</th>
<th>Other</th>
<th>TOTAL LEARNERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Video 1: AHR</td>
<td>737</td>
<td>15</td>
<td>752</td>
</tr>
<tr>
<td>Video 2: Clinical Significance of AHR</td>
<td>696</td>
<td>2</td>
<td>698</td>
</tr>
<tr>
<td>Monograph</td>
<td>664</td>
<td>11</td>
<td>675</td>
</tr>
</tbody>
</table>
Level (1) Outcomes: Participation (Specialty)
Final Outcomes Summary – Online Enduring Outcomes

99% of learners across the 3 activities were in the target audience

N=2,125

### Video 1: AHR

<table>
<thead>
<tr>
<th>Specialty</th>
<th>Learners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy/Immunology</td>
<td>276</td>
</tr>
<tr>
<td>Pulmonology</td>
<td>461</td>
</tr>
<tr>
<td>Other</td>
<td>15</td>
</tr>
<tr>
<td><strong>TOTAL LEARNERS</strong></td>
<td><strong>752</strong></td>
</tr>
</tbody>
</table>

### Video 2: Clinical Significance of AHR

<table>
<thead>
<tr>
<th>Specialty</th>
<th>Learners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy/Immunology</td>
<td>322</td>
</tr>
<tr>
<td>Pulmonology</td>
<td>374</td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
</tr>
<tr>
<td><strong>TOTAL LEARNERS</strong></td>
<td><strong>698</strong></td>
</tr>
</tbody>
</table>

### Monograph

<table>
<thead>
<tr>
<th>Specialty</th>
<th>Learners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy/Immunology</td>
<td>290</td>
</tr>
<tr>
<td>Pulmonology</td>
<td>374</td>
</tr>
<tr>
<td>Other</td>
<td>11</td>
</tr>
<tr>
<td><strong>TOTAL LEARNERS</strong></td>
<td><strong>675</strong></td>
</tr>
<tr>
<td>Evaluation Outcome</td>
<td>Response Rate</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Meeting the learning objectives</td>
<td>98%</td>
</tr>
<tr>
<td>Meeting your educational needs</td>
<td>98%</td>
</tr>
<tr>
<td>Reinforcing and/or improving current skills</td>
<td>98%</td>
</tr>
<tr>
<td>Giving you tools and strategies to apply in practice</td>
<td>97%</td>
</tr>
<tr>
<td>Improving your ability to treat or manage patients</td>
<td>96%</td>
</tr>
</tbody>
</table>

98% reported the material was presented without commercial bias (N=224)

100% reported the content was evidence-based and clinically relevant (N=224)
Overall Knowledge Gain across Learning Objectives
Across All 3 Activities

62% Relative Knowledge Gain
31% Absolute Knowledge Gain

50% 81%

Pre-test (AVG N=173) Post-test (AVG N=78)
Learning Objective: Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma

Question 1 (Video 1): Which of the following is least likely to be involved in airway hyperresponsiveness in asthma?

a. Airway epithelium
b. Mast cells
c. Airway smooth muscle
d. Neutrophils
e. TH2 cells
Level (3 & 4) Outcomes: Knowledge & Competence
Final Outcomes Summary – Online Enduring Outcomes

Learning Objective: Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management.

Question 2 (Video 1): Manny is an 18-year-old male who states that he has coughing and wheezing whenever he is around his friend's dogs and prolonged cough whenever he gets a cold. He has no pets at home since he is known to be allergic to dogs based on skin testing performed about 5 years ago. He is feeling well today. On pulmonary testing today, he has a normal exhaled nitric oxide and normal lung function, without bronchodilator reversibility. You decide to use a bronchial provocation test (BPT) to help understand his respiratory symptoms given his normal pulmonary testing thus far. Which of the following is an example of a direct BPT used commonly in clinical practice to assess for airway hyperresponsiveness?

a. Histamine challenge
b. Methacholine challenge
c. Mannitol challenge
d. Allergen challenge
Learning Objective: *Discuss the implications of AHR for treatment selection in severe asthma.*

**Question 3 (Video 2):** Cassie is a 26-year-old female with severe persistent asthma. Her exhaled nitric oxide, total IgE level, and circulating eosinophil counts are all elevated. She continues to require her rescue inhaler 4-5 times a week and have occasional nighttime awakening despite being on high-dose ICS/LABA/LAMA therapy. Prior to starting therapy, she was noted to have significant airway hyperresponsiveness on methacholine challenge, with a PC₂₀ of 0.25. Repeat methacholine challenge now demonstrates a PC₂₀ of 3.2mg/ml. Which would be your next intervention?

a. No further intervention as her AHR has improved so much after starting ICS/LABA/LAMA therapy
b. Add a biologic agent such as tezepelumab for continued poor control of her severe persistent asthma and continued AHR
c. Switch to a different ICS/LABA/LAMA inhaler as the current one does not seem to be fully controlling her asthma
d. Prescribe imatinib for her asthma
Level (3 & 4) Outcomes: Knowledge & Competence

Final Outcomes Summary – Online Enduring Outcomes

Learning Objective: *Compare the effects of current and emerging biologic therapies on AHR in clinical studies*

**Question 4 (Video 2):** Which of the following therapies has been shown to consistently reduce airway hyperresponsiveness?

1. Tyrosine kinase inhibition with imatinib
2. Anti-IgE therapy with omalizumab
3. Anti-TSLP therapy with tezepelumab
4. Anti-IL-5 therapy with reslizumab
5. A and C
6. B and C

Of note, “other” learners demonstrated a knowledge decrease with regard to comparing the effects of biologics on AHR in clinical studies. However, because allergists and pulmonologists demonstrated significant gains, faculty determined it was not necessary to revise the question.
Learning Objective: Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma

Question 5 (Monograph): Which of the following is true about the alarmins and their role in airway hyperresponsiveness (AHR) in asthma?

a. They are the primary cytokines involved in eosinophil differentiation and activation
b. They cause mast cell degranulation by binding to Fc epsilon receptors
c. They increase AHR through their effects on type 2 and non-type 2 inflammation
d. They are rapidly released by goblet cells in response to pollutants and allergens
Learning Objective: Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management

Question 6 (Monograph): A 40-year-old woman has severe uncontrolled asthma despite treatment with an inhaled corticosteroid, a long-acting beta-2 agonist, and a long-acting muscarinic antagonist. Her peripheral blood eosinophil count is 200 cells/µl. You decide that bronchoprovocation testing could provide insight into whether type 2 airway inflammation is driving her symptoms. The results of which of the following bronchoprovocation tests has been shown to correlate closely with the presence of biomarkers of type 2 airway inflammation?

a. Mannitol challenge
b. Adenosine monophosphate (AMP) challenge
c. Histamine challenge
d. Eucapnic voluntary hyperventilation challenge
Learning Objective: Discuss the implications of AHR for treatment selection in severe asthma

Question 7 (Monograph): 32-year-old man with severe asthma has uncontrolled symptoms despite treatment with 8 months of an anti–IL-5 biologic, in addition to a high-dose inhaled corticosteroid, a long-acting beta-2 agonist, and a long-acting muscarinic antagonist. His peripheral blood eosinophil count decreased from 475 cells/µl to 250 cells/µl on an anti–IL-5 therapy. His methacholine PC20 is 1.8 mg/mL (normal > 16 mg/mL) and unchanged. His FEV1 is unchanged. He has no history of atopy, and skin prick testing to common aeroallergens is negative. You stop the anti–IL-5 biologic because the clinical response was insufficient. He will continue his inhaled medications. Which of the following represents the next best treatment step?

a. Begin a 3-week oral corticosteroid taper
b. Begin a 12-week trial of an oral macrolide antibiotic
c. Begin a biologic therapy that targets immunoglobulin E
d. Begin a biologic therapy that targets thymic stromal lymphopoietin
Learning Objective: Compare the effects of current and emerging biologic therapies on AHR in clinical studies

Question 8 (Monograph): A 53-year-old woman has severe asthma. Her peripheral blood eosinophil count has always been normal. Despite treatment with a high-dose inhaled corticosteroid, a long-acting beta-2 agonist, and a long-acting muscarinic antagonist, she continues to have intense bouts of coughing and shortness of breath, particularly on high-pollution days and with respiratory viral infections. Severe airway hyperresponsiveness is present; her methacholine PC20 is 0.12 mg/mL (normal > 16 mg/mL). Treatment with which of the following biologic therapies has been shown in clinical trials to reduce airway hyperresponsiveness in individuals with severe asthma?

a. Mepolizumab  
b. Dupilumab  
c. Benralizumab  
d. Tezepelumab
Level (4) Outcomes: Competence (Across 3 Activities)

Final Outcomes Summary – Online Enduring Outcomes

Evaluation respondents reported their confidence as it relates to the learning objectives before and after the activity (Very confident – confident)

<table>
<thead>
<tr>
<th>Objective</th>
<th>Before activity (AVG N=148)</th>
<th>After activity (AVG N=72)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma</td>
<td>60%</td>
<td>95%</td>
</tr>
<tr>
<td>Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management</td>
<td>59%</td>
<td>94%</td>
</tr>
<tr>
<td>Discuss the implications of AHR for treatment selection in severe asthma</td>
<td>59%</td>
<td>93%</td>
</tr>
<tr>
<td>Compare the effects of current and emerging biologic therapies on AHR in clinical studies</td>
<td>52%</td>
<td>91%</td>
</tr>
</tbody>
</table>

Compare the effects of current and emerging biologic therapies on AHR in clinical studies

Discuss the implications of AHR for treatment selection in severe asthma

Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management

Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma
What change will you incorporate into your practice as a result of the knowledge acquired during the activity?

- Evaluate AHR to classify asthma severity: 18%
- Consider AHR when characterizing asthma type: 21%
- Perform direct bronchial provocation challenge testing as part of asthma workup: 5%
- Perform indirect bronchial provocation challenge testing as part of asthma workup: 5%
- Consider inhaled corticosteroids when indicated for AHR: 11%
- Consider bronchodilators when indicated for AHR: 9%
- Consider tyrosine kinase inhibitors when indicated for AHR: 7%
- Consider biologics when indicated for AHR: 14%
- Other: 1%
- N/A: 4%

*N=584*

*Evaluation respondents were able to select more than one answer*
### What barriers will the education provided help to address?

- Accurate diagnosis and treatment
- Allergy referrals
- Better management strategies
- Best options for continued care
- Clarification around clinical practice guidelines
- Hesitancy in constructing a BPT in those with occupational asthma

### What barriers to optimal patient care are you facing that were not addressed in this activity?

- Availability of resources
- Cannot do EVH or mannitol here
- Cost of biologics
- Insurance coverage
- Medication coverage

- Improved understanding of various biologics and when to use each one
- Insurance payments and cost
- Lack of time
- Patient cooperation

- Reimbursement and prior authorization
- Resource availability
- Time and cost
Key Takeaways

• Already implemented what was presented
• Assessing AHR in patients with normal PFTs
• Asthma is very complicated!
• Better information about tezepelumab
• Consider different phenotypes for the management of severe persistent asthma with the use of new biologics
• Importance of screening asthma patients
• Multifaceted disease
• Multiplicity of AHR causes and mechanisms
• Pulmonology consultation is valuable
• Receptor mediated responsiveness
• TSLP therapy treats higher up in cascade
• Use of methacholine
• Using AHR assessment tools to guide selection of therapy options
• Understanding of the pathways and contributors to airway hyperresponsiveness
• Value of BPT as aid in management
• When to think about switching biologics
• Which biologics target certain inflammatory agents

Future Topics

• Adequate control of asthma symptoms
• Association with sinusitis and allergic rhinitis
• Biologic therapies
• Bronchial thermoplasty
• Combination biologic therapies
• Direct treatment
• Discussion on mucosal microenvironment
• Impact of new therapies
• New emerging agents for treatment of AHR
• Occupational asthma
• Pediatric asthma
• Relation to sleep
• Role of FeNO
• TH2 cell types

“It was very well presented and personally I learned a lot about newer diagnostic and treatment therapies.”
– Online enduring learner
National Jewish Health is accredited with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The NJH Office of Professional Education produced and accredited this program and adhered to the updated ACCME guidelines.

**Video Activities**
NJH designates each enduring material for a maximum of 0.25 *AMA PRA Category 1 Credit™*. 

**Monograph**
NJH designates this enduring material for a maximum of 0.5 *AMA PRA Category 1 Credit™*. 
